S Filgrastim Sweet's syndrome: case reportA 53-year-old woman developed Sweet's syndrome while receiving filgrastim.The woman was receiving filgrastim [dosage and route not stated] as adjuvant therapy to manage febrile neutropenia, after being diagnosed with acute myeloid leukaemia. In addition, she was receiving induction chemotherapy with daunorubicin and cytarabine. She developed an increase in lesions in the form of blisters and haemorrhagic pustules, surrounded by sensitive inflammatory plaques on her limbs, neck and face, 13 days after chemotherapy. The lesions were associated with arthralgia, myalgia and high fever. She had headaches and developed conjunctivitis and erosions affecting her mucous membranes and tongue, associated with gingival hyperplasia. Findings of a biopsy of her cutaneous lesions were consistent with Sweet's syndrome.The woman started IV hydrocortisone; her cutaneous lesions improved significantly. However, she died due to respiratory and heart failure before the start of the second chemotherapy cycle. No autopsy was carried out.